ABBV

On Monday, biopharmaceutical giant AbbVie Inc. (NYSE:ABBV) agreed to acquire Apogee Therapeutics Inc. (NASDAQ:APGE) in a cash deal valued at approximately $10.9 billion.

AbbVie shares jump after its $10.9B Apogee deal adds late-stage eczema and respiratory candidates, deepening its immunology pipeline.

Canada is the first country to approve a new botulinum neurotoxin serotype for aesthetic use Boey ® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved for the temporary improvement in the appearance of glabellar lines Boey® offers a differentiated treatment option for many people who are curious about facial injectables Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks BOTOX Cosmetic ® (onabotulinumtoxinA) is the only neurotoxin clinically tested for use following treatment with Boey ® IRVINE, Calif., June 23, 2026 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced Health Canada has approved Boey® (trenibotulinumtoxinE) for the temporary improvement in the appearance of moderate to severe lines between the eyebrows (glabellar lines) in adult patients.

Big pharma's appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology developer, has reignited a question every healthcare portfolio manager is asking: who will be next?

These players sell market-leading products and are tackling growth industries. Holding for several years, rather than a short period, allows investors to fully benefit from each company's story.

MAVIRET ® (glecaprevir/pibrentasvir) is now approved in the European Union for the treatment of acute hepatitis C virus (HCV) infection with compensated liver disease (with or without cirrhosis) in adults and children aged 3 years and older. The approval gives clinicians an option to initiate treatment as soon as acute infection is confirmed, aiming to reduce delays in care and lower the risk of liver disease progression, cirrhosis and liver cancer.

SKYRIZI ® (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasis 1 Approval was based on the pivotal Phase 3 OptIMMize-1 and OptIMMize-2 trials which include a new 55 mg pre-filled syringe to support weight-based dosing for patients weighing less than 40 kg 1 Nearly a third of people living with psoriasis develop symptoms before the age of 18, often getting lesions on highly visible areas 2,3 NORTH CHICAGO, Ill., June 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved SKYRIZI® (risankizumab) for the treatment of children and adolescents six years of age and older with moderate to severe plaque psoriasis who are candidates for systemic therapy.

AbbVie is making smart moves to bolster its lucrative immunology business. The healthcare leader is working to diversify its sales and profits.

The deal gives the company a strong asset in zumilokibart, Apogee's very promising investigational drug. Apogee stockholders are to be paid $135.11 per share in the all-cash transaction.

On June 22, 2026, Apogee Therapeutics shares surged as investors reacted to AbbVie's proposed acquisition terms.